HomeSmall Caps
Share

Huang's exit may weaken Nvidia. Which small caps stand to gain as rivals win orders?

Aldiyar Anuarbekov

Aldiyar Anuarbekov

analyst
Any slowdown in Nvidia’s execution would give its rivals a chance to close the gap, says Omdia chief analyst Lian Jye Su / Photo: Shutterstock.com

Any slowdown in Nvidia’s execution would give its rivals a chance to close the gap, says Omdia chief analyst Lian Jye Su / Photo: Shutterstock.com

Nvidia shares fell 4.3% after Jensen Huang resigned as the chipmaker's CEO on Thursday, while rivals AMD and Broadcom each gained more than 5%. If the leadership change slows the rollout of new Nvidia chips, big customers could buy more AMD accelerators and invest more in developing their own chips, experts say. Oninvest analyst Aldiyar Anuarbekov looks at which other companies could benefit.

Implications of Huang’s ouster

On Thursday, Nvidia said that cofounder Jensen Huang had stepped down as CEO and president and left the board. CFO Colette Kress became interim CEO while retaining her role as CFO. Nvidia shares opened 13.1% below the previous close, fell as much as 14.3% during Thursday's session, and ended the day down 4.3%.

That same day, William Blair upgraded AMD to “outperform” and downgraded Nvidia to “market perform.” It sees scope for AMD to gain share in the AI accelerator market with its Instinct line and sell more server processors through its custom chip programs.

The change in leadership at Nvidia is unlikely to materially alter purchasing in the near term, Minotaur Capital portfolio manager Armina Rosenberg told Reuters. She said the chips Nvidia will ship over the next year or two have already been designed and are in production, and customers’ 2027 spending plans do not depend on who runs the company. Still, any slowdown in Nvidia’s execution would give rivals more room to catch up, argues Lian Jye Su, chief analyst at Omdia.

Potential beneficiaries of Nvidia turmoil

If cloud providers and AI developers accelerate work on alternatives to Nvidia chips, suppliers of chip design and testing technology could pick up additional orders. Oninvest identified three small companies with projects already underway. Cohu is seeing its semiconductor test handlers being tested, Aehr is set to sell a chip test system to a major supplier of AI accelerators, and Arteris has licensed its interconnect technology to AMD for use in its next generation of chips.

Cohu (COHU)

Cohu, which has a market capitalization of $2 billion, supplies semiconductor test equipment. Its Eclipse handlers keep high-power processors at the required temperature during testing. In the third quarter, Cohu’s revenue rose 37% year over year to $173 million, and adjusted earnings came in at $0.43 per share versus an adjusted loss of $0.06 per share a year earlier. The company attributes rising demand for Eclipse to more complex chips, higher power levels, and tighter testing requirements.

Cohu estimated that the customer projects it was pursuing for its Eclipse chip-testing systems represented around $1 billion in possible sales per year, up 18% from the previous quarter. That figure includes projects at various stages, including some where customers are still evaluating the equipment. The management expects to ship three times as many Eclipse handlers in 2027 as in 2026. On November 10, Cohu said a fourth customer had qualified the platform for testing high-performance chips. Cohu has kept the customers’ names confidential, though CEO Luis Müller said they include major cloud providers and chip designers that work with them. One computing customer accounted for more than 10% of Cohu’s total quarterly revenue.

After the quarterly report, Jefferies maintained its “buy” rating and raised its target price to $90 per share from $74 per share. The new TP is about double the Friday closing price. Craig-Hallum also reiterated its “buy” rating and raised its TP to $74 per share from $65 per share. According to MarketWatch data, the stock has eight bullish analyst ratings, with an average TP of $73 per share.

Arteris (AIP)

Arteris licenses technology that lets blocks on a chip and individual chiplets exchange data, collecting licensing fees and royalties on the chips produced. Its market capitalization is less than $1 billion. In August 2025, AMD licensed its FlexGen technology for next-generation AI chips. In September this year, when Arteris unveiled an expanded lineup of products for multidie chips, AMD Senior Director of Silicon Design Jason Miller said the collaboration gives AMD early access to technology that simplifies chiplet integration.

In the third quarter, Arteris revenue rose 48% year over year to $25.8 million. Annual contract value plus royalties reached $103.8 million, up 39% from a year earlier. One of the largest cloud providers and two of the top 10 semiconductor companies expanded their use of Arteris technology to design chips and chiplets, including AI accelerators and data center processors. The company's net loss widened to $11.2 million from $9 million a year earlier. Arteris flags another risk: large chip designers could develop similar technology in-house.

On November 6, Oppenheimer reiterated its “buy” rating but lowered its TP to $30 per share from $40 per share. The new TP still implies 55% upside from Friday's close. TD Cowen had previously maintained its “buy” rating while cutting its TP to $25 per share from $40 per share, implying 30% upside. The stock has seven “buy” ratings, with an average TP of $33 per share.

Aehr Test Systems (AEHR)

Aehr, which has a market capitalization of less than $2 billion, makes systems that test chip reliability under load and at high temperatures. In the first quarter of the company's fiscal 2027, ended September 25, revenue tripled to a record $33 million from $11 million a year earlier. Net income was $7.2 million versus a net loss of $2.1 million in the same time frame. The management raised its full-year revenue guidance to $150 million, the top of its previous $130-150 million range.

Aehr said a major AI accelerator supplier had decided to buy a FOX-XP system for testing at a partner’s facility in Taiwan. Installation is scheduled for early 2027. The management expects a decision on whether the system will be used in volume production within several months of installation and validation. It estimates that customers could need five to 10 systems for every million accelerators they produce annually. Aehr reckons that this could generate $35-70 million in revenue, including consumables. In fiscal 2026, Aehr’s five largest customers accounted for around 70% of revenue versus 77% a year earlier.

On November 3, Jefferies maintained its “buy” rating but lowered its TP to $140 per share from $175 per share. That implies around 145% upside from the Friday close. Oppenheimer also reiterated its “buy”-equivalent rating that day and kept its TP at $120 per share. The stock has seven “buy” ratings, with an average TP of $120.80 per share.

Drivers for the stocks

If AMD sells more chips that use Arteris technology, Arteris could collect more royalties. Cohu and Aehr could pick up additional orders if developers of competing accelerators choose their equipment for production testing. For Cohu, the next milestone is customers moving Eclipse into volume testing. For Aehr, it is the customer’s decision on FOX-XP after trials in Taiwan.

Neil Shah, vice president of research at Counterpoint Research, said Nvidia could slow its investments in its ecosystem and take longer to strike major infrastructure deals after Huang’s departure. The next events for the market to watch are Nvidia’s quarterly results and call with analysts, both scheduled for Tuesday.

This text is for informational purposes only and does not constitute personalized investment advice.

Share

Trending

Stock Screener
Buy
Sell
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
Small Caps
Investment and Finance News